Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and leukemia group B trial 30407

Journal of Clinical Oncology

Volumn 29, Issue 23, 2011, Pages 3120-3125

  Govindan, Ramaswamy ^a   Bogart, Jeffrey ^b   Stinchcombe, Thomas ^c   Wang, Xiaofei ^d   Hodgson, Lydia ^d   Kratzke, Robert ^f   Garst, Jennifer ^d   Brotherton, Timothy ^e   Vokes, Everett E ^g  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e Southeast Cancer Control Consortium   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB; PEMETREXED;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; DEHYDRATION; DRUG ERUPTION; DYSPHAGIA; DYSPNEA; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPOKALEMIA; LEUKEMIA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; FEMALE; GLUTAMATES; GUANINE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING;

EID: 80051742422     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.4979     Document Type: Article

References (28)

1. Govindan R., Page N., Morgensztern D., et al: Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24:4539-4544, 2006 (Pubitemid 46630948)
2. Jemal A., Siegel R., Xu J., et al: Cancer statistics, 2010. CA Cancer J Clin 60:277-300, 2010
3. Yang P., Allen M.S., Aubry M.C., et al: Clinical features of 5,628 primary lung cancer patients: Experience at Mayo Clinic from 1997 to 2003. Chest 128:452-462, 2005 (Pubitemid 40994510)
4. Pfister D.G., Johnson D.H., Azzoli C.G., et al: American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: Update 2003. J Clin Oncol 22:330-353, 2004 (Pubitemid 41095099)
5. Hanna N., Neubauer M., Yiannoutsos C., et al: Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: The Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 26:5755-5760, 2008
6. Albain K.S., Swann R.S., Rusch V.W., et al: Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: A phase III randomised controlled trial. Lancet 374:379-386, 2009
7. Vokes E.E., Herndon J.E. 2nd, Crawford J., et al: Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and Leukemia Group B study 9431. J Clin Oncol 20:4191-4198, 2002 (Pubitemid 35191021)
8. Segawa Y., Kiura K., Takigawa N., et al: Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol 28:3299-3306, 2010
9. Yamamoto N., Nakagawa K., Nishimura Y., et al: Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol 28:3739-3745, 2010
10. Hanna N., Shepherd F.A., Fossella F.V., et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597, 2004 (Pubitemid 41079796)
11. Ciuleanu T., Brodowicz T., Zielinski C., et al: Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small- cell lung cancer: A randomised, double-blind, phase 3 study. Lancet 374:1432-1440, 2009
12. Scagliotti G.V., Parikh P., Von Pawel J., et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3551, 2008
13. Seiwert T.Y., Connell P.P., Mauer A.M., et al: A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res 13:515-522, 2007 (Pubitemid 46225357)
14. Thienelt C.D., Bunn P.A. Jr, Hanna N., et al: Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol 23:8786-8793, 2005 (Pubitemid 46211524)
15. Rosell R., Robinet G., Szczesna A., et al: Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 19:362-369, 2008 (Pubitemid 351201721)
16. Robert F., Blumenschein G., Herbst R.S., et al: Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol 23: 9089-9096, 2005
17. Bonner J.A., Harari P.M., Giralt J., et al: Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high-dose radiation therapy with and without cetuximab. J Clin Oncol 22: 489s, 2004 (suppl; abstr 5507)
18. Vokes E.E., Herndon J.E. 2nd, Kelley M.J., et al: Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 25:1698-1704, 2007 (Pubitemid 46797950)
19. Socinski M.A., Blackstock A.W., Bogart J.A., et al: Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol 26:2457-2463, 2008
20. Therasse P., Arbuck S.G., Eisenhauer E.A., et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
21. Calvert A., Newell D., Gumbrell L., et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989 (Pubitemid 19272848)
22. US Food and Drug Administration: Pemetrexed package insert. http://www.accessdata.fda.gov/drugsatfda-docs/label/2004/021462ppilbl.pdf
23. ImClone Systems, Bristol-Myers Squibb: Erbitux (cetuximab) package insert. http://www.erbitux.com/index.aspx
24. Kaplan E.L., Meier P.: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
25. Akerley W., Herndon J.E. Jr, Lyss A.P., et al: Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: A limited-access study-CALGB 9534. Clin Lung Cancer 7:47-53, 2005
26. Vokes EE, Senan S, Treat JA, et al: PROCLAIM: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology. Clin Lung Cancer 10:193-198, 2009
27. Pirker R., Pereira J.R., Szczesna A., et al: Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomised phase III trial. Lancet 373:1525-1531, 2009
28. Blumenschein G.R., Moughan J., Curran W., et al: A phase II study of cetuximab (C225) in combination with chemoradiation: B3-07. J Thorac Oncol 2:S342-S343, 2007 (suppl 4)